Generare Bioscience

Generare Bioscience is a biotechnology firm aiming to revitalize the discovery of medicines derived from natural products. Founded in Paris in 2023 by CEO Guillaume Vandenesch and CSO Dr. Vincent Libis, the company addresses the recent plateau in discovering new drugs from natural sources, a historically fruitful avenue for pharmaceuticals. Vandenesch is a serial entrepreneur who previously scaled the deep-tech accelerator Hello Tomorrow and exited a venture to Capgemini, while Dr. Libis is a seasoned researcher in synthetic biology who co-founded Abolis Biotechnologies and holds a Chair on Antibiotic Resistance at INSERM. Their combined expertise underpins Generare's data-driven platform, which is the culmination of a decade of research in synthetic biology, DNA sequencing, and computational biology.

The company's core technology bypasses the limitations of traditional discovery methods. Instead of slow, expensive, and constrained techniques that target specific gene clusters, Generare employs a method called "shotgun cloning". This process involves breaking down the genomes of thousands of soil bacteria into millions of random fragments. Each fragment is then cloned and analyzed in parallel to identify bioactive molecules, such as those with antibiotic or anticancer properties. This parallel approach exponentially increases the probability of finding valuable compounds and has already enabled the identification of over 100 previously unknown molecules. By gathering more data, the platform creates a virtuous cycle, improving its ability to predict which genetic clusters are most likely to yield useful molecules and expanding its proprietary molecular library.

Generare operates in the biotech and pharmaceutical sectors, with potential applications in cosmetics and agriculture. Its business model focuses on leveraging its discovery platform to identify high-potential novel molecules for the pharmaceutical industry. The company establishes strategic partnerships to accelerate the development of these discoveries, such as its collaboration with French biotech firm Aurobac Therapeutics. In October 2024, Generare secured €5 million in a seed funding round from investors including Teampact.ventures, Galion.Exe, and VIVES Partners. This capital is being used to refine the technology, expand its genetic data library, and industrialize its discovery process into a scalable "discovery factory".

Keywords: drug discovery, natural products, synthetic biology, microbial DNA, shotgun cloning, computational biology, bioactive molecules, pharmaceutical development, antibiotics, anticancer, biotechnology, agritech, deep tech, therapeutics, genetic engineering, DNA sequencing, metabolite expression, molecular library, biosynthesis, genomics